4.5 Review

Testosterone in the brain: Neuroimaging findings and the potential role for neuropsychopharmacology

期刊

EUROPEAN NEUROPSYCHOPHARMACOLOGY
卷 23, 期 2, 页码 79-88

出版社

ELSEVIER
DOI: 10.1016/j.euroneuro.2012.04.013

关键词

Testosterone; Brain; Neuroimaging; Sex differences; Androgen; PET; fMRI

资金

  1. AstraZeneca
  2. Bristol-Myers Squibb
  3. CSC
  4. Eli Lilly
  5. GlaxoSmithKline
  6. Janssen
  7. Lundbeck
  8. Merck Sharp and Dome (MSD)
  9. Novartis
  10. Organon
  11. Pierre Fabre
  12. Pfizer
  13. Schwabe
  14. Sepracor
  15. Servier
  16. Wyeth
  17. H. Lundbeck A/S

向作者/读者索取更多资源

Testosterone plays a substantial role in a number of physiological processes in the brain. It is able to modulate the expression of certain genes by binding to androgen receptors. Acting via neurotransmitter receptors, testosterone shows the potential to mediate a non-genomic so-called neuroactive effect. Various neurotransmitter systems are also influenced by the aromatized form of testosterone, estradiol. The following article summarizes the findings of preclinical and clinical neuroimaging studies including structural and functional magnetic resonance imaging (MRI/fMRI), voxel based morphometry (VBM), as well as pharmacological fMRI (phfMRI) and positron emission tomography (PET) regarding the effects of testosterone on the human brain. The impact of testosterone on the pathogenesis of psychiatric disorders and on sex-related prevalence differences have been supported by a wide range of clinical studies. An antidepressant effect of testosterone can be implicitly explained by its effects on the limbic system - especially amygdala, a major target in the treatment of depression - solidly demonstrated by a large body of neuroimaging findings. (c) 2012 Elsevier B.V. and ECNP. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据